Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q1 FY23 results · Apr–Jun 2022
Torrent Pharmaceuticals reported revenue from operations of ₹2,347.00 crore (up 10.0% from Q1 FY22) and net profit of ₹354.00 crore (up 7.3% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,347.00 | 2,134.00 | +10.0% | 2,131.00 | +10.1% |
| Other income | 30.00 | 40.00 | −25.0% | 56.00 | −46.4% |
| Total income | 2,377.00 | 2,174.00 | +9.3% | 2,187.00 | +8.7% |
| Profit before tax | 532.00 | 484.00 | +9.9% | (87.00) | Turned profit |
| Net profit for the period | 354.00 | 330.00 | +7.3% | (118.00) | Turned profit |
| EPS, basic (₹) | 20.90 | 19.53 | +7.0% | (6.98) | Turned profit |
| Net margin (%) | 15.1 | 15.5 | -5.5 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,933.00 | 1,695.00 | +14.0% | 1,662.00 | +16.3% |
| Other income | 29.00 | 50.00 | −42.0% | 61.00 | −52.5% |
| Total income | 1,962.00 | 1,745.00 | +12.4% | 1,723.00 | +13.9% |
| Profit before tax | 494.00 | 412.00 | +19.9% | 345.00 | +43.2% |
| Net profit for the period | 327.00 | 274.00 | +19.3% | 221.00 | +48.0% |
| EPS, basic (₹) | 19.35 | 16.21 | +19.4% | 13.08 | +47.9% |
| Net margin (%) | 16.9 | 16.2 | 13.3 |
Consolidated
- Filed with BSE
- 30 Jul 2022, 12:51 IST
- Board meeting
- 29 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jul 2022, 12:51 IST
- Board meeting
- 29 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Audited
- Source
- XBRL filing on BSE